Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Search

Page Path
HOME > Search
1 "Rajpal S. Kashyap"
Filter
Filter
Article category
Keywords
Publication year
Authors
Perspective
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
Aliabbas A. Husain, Andreas Kupz, Rajpal S. Kashyap
Epidemiol Health. 2021;43:e2021022.   Published online April 7, 2021
DOI: https://doi.org/10.4178/epih.e2021022
  • 32,832 View
  • 526 Download
  • 12 Web of Science
  • 15 Crossref
AbstractAbstract AbstractSummary PDF
Abstract
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
Summary
Key Message
India is regarded as highest drug-resistant TB burden country accounting for estimated 27% of global cases. Challenge of addressing drug resistant TB is critical for India to achieve TB elimination targets of National TB program. Several heterogeneous factors have mediated the success of DR-TB management in India. In this article, we discuss, in brief, some of the major challenges and implications associated with reducing the growing DR-TB epidemic in India.

Citations

Citations to this article as recorded by  
  • Strengthening the National Reference Laboratory in the Republic of Congo: An Investment Imperative for Tuberculosis Diagnostics
    Darrel Ornelle Elion Assiana, Franck Hardain Okemba-Okombi, Salomon Tchuandom Bonsi, Freisnel Hermeland Mouzinga, Juliet E. Bryant, Jean Akiana, Tanou Joseph Kalivogui, Alain Disu Kamalandua, Nuccia Saleri, Lionel Caruana, Hugues Traoré Asken, Dissou Affo
    Tropical Medicine and Infectious Disease.2026; 11(1): 23.     CrossRef
  • Bridging gaps in tuberculosis control: addressing cross-border challenges between India and Pakistan
    Harendra Kumar, Fnu Teena, Aneeta Bai, Love Kumar, Sebastian Gallego
    Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2025; 39: 100526.     CrossRef
  • Strategies and Recent Advances in Tackling Antibacterial Resistance in India: A Comprehensive Narrative Review
    Tanmay Goudar, Shreyas Desai, Manjunatha Basappa
    Cureus.2025;[Epub]     CrossRef
  • Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990–2035): implications for achieving global end TB goals
    Yunbin Yang, Aoran Yang, Renzhong Li, Wei Su, Jiawen Jiang, Liangli Liu, Yunzhou Ruan, Lin Xu
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma–Experience from Asian Countries
    Cinnie Soekojo, Shimin Jasmine Chung, Ming-Tao Tsai, Wenming Chen, Jeffrey Huang, Jin Seok Kim, Dong-Gun Lee, Chang Ki Min, Kazuhito Suzuki, Subramanian Swaminathan, Hiroyuki Takamatsu, Daryl Tan, Uday Yanamandra, Chandramouli Nagarajan, Wee Joo Chng
    Clinical Lymphoma Myeloma and Leukemia.2025;[Epub]     CrossRef
  • Efficacy and safety data on pretomanid for drug-resistant TB
    H.T.T. Thuy, C. Padmapriyadarsini, C. Chuchottaworn, S. Foraida, S. Hadigal, A.R. Birajdar
    IJTLD Open.2025; 2(2): 73.     CrossRef
  • Enhancing Tuberculosis Treatment Adherence: Evaluating the Efficacy of the Support for Treatment Adherence and Medication Protocols (STAMP) Device for Automatic Dispensing and Real-Time Medication Monitoring
    Simon Chandramohan Jason Charles, Krishna Anusha, Krishna Mahesh, Ramachandran Ramasubramanian, Perumal Kaliraj, Vimalraj Selvaraj
    Cureus.2024;[Epub]     CrossRef
  • Rifampicin-resistant Tuberculosis: A Global Health Dilemma
    Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Mainul Haque
    Advances in Human Biology.2024; 14(2): 87.     CrossRef
  • Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases
    Aparna Bhanushali, Sachin Atre, Preethi Nair, Geethanjali Anilkumar Thandaseery, Sanchi Shah, Sanjana Kuruwa, Amrutraj Zade, Chaitali Nikam, Mangala Gomare, Anirvan Chatterjee, Arryn Craney
    Microbiology Spectrum.2024;[Epub]     CrossRef
  • Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study
    Priyanka Joshi, Krishna G Singh, Vishal Patidar, Vikas Gupta
    Cureus.2024;[Epub]     CrossRef
  • Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends
    Hui-Wen Song, Jian-Hua Tian, Hui-Ping Song, Si-Jie Guo, Ye-Hong Lin, Jin-Shui Pan
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • The Crosstalk Between HIV-TB Co-Infection and Associated Resistance in the Indian Population
    Sushama Jadhav, Aishwarya Nair, Pratik Mahajan, Vijay Nema
    Venereology.2024; 3(4): 183.     CrossRef
  • Prevalence, patterns, and determinants of drug-resistant tuberculosis in Gulf Cooperation Council countries: an updated systematic review
    Alaa Alibrahim, Homoud Alqahtani, Ashokkumar Thirunavukkarasu, Ibtisam Qazi
    PeerJ.2024; 12: e18628.     CrossRef
  • Double trouble: compounding effects of COVID-19 pandemic and antimicrobial resistance on drug resistant TB epidemiology in India
    Aliabbas A. Husain, Rajpal Singh Kashyap
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Snapshot of Mycobacterium tuberculosis Phylogenetics from an Indian State of Arunachal Pradesh Bordering China
    Shiv kumar Rashmi Mudliar, Umay Kulsum, Syed Beenish Rufai, Mika Umpo, Moi Nyori, Sarman Singh
    Genes.2022; 13(2): 263.     CrossRef
Epidemiol Health : Epidemiology and Health
© Korean Society of Epidemiology.
TOP